



Zeyu Li Partner

Practice Areas: Private Equity/Venture Capital, Mergers & Acquisitions, Investment Funds

E-mail: zeyu.li@meritsandtree.com

Tel: 021-5253 3530

Professional Experience

Zeyu Li is a partner at Merits & Tree. Prior to joining Merits & Tree, Ms. Li was a partner at Zhonglun Law Firm.

Ms. Li has extensive experience in Private Equity/Venture Capital, Mergers & Acquisitions, Cross-border Licensing Transactions and Corporate Compliance. Over the past decade, the total amount of the deals involved by Ms. Li has been up to tens of billions of US dollars. Her clients cover leading investment institutions, start-up companies, and multinational companies in high-tech fields such as pharmaceutical and semiconductors. Ms. Li is good at seeking a balance of interests among parties in complex transactions, so as to facilitate clients to achieve their ultimate business goals with her professional legal services.

Education

LL.M., International Business Law, London School of Economics (LSE)

Finance MBA, China Europe International Business School

LL.B., Zhongnan University of Economics and Law

B.A., English Literature, Huazhong University of Science and Technology

Qualifications

Ms. Li has been admitted to practice in the People's Republic of China

Working language

Chinese and English

Representative Cases

1. Private Equity/Venture Capital

Ms. Li's experience includes providing legal services for:

- Hong Kong Asia Medical Group (a leading brand of cardiovascular medical care in Asia) in its US\$400 million Series D financing;
- ImmuneOnco (anti-tumor biotechnology) in its nearly US\$100 million cross-round financing;
- NewMed Medical (heart valve replacement) in its over US\$100 million Series C financing;

- ST Phi Therapeutics (Car-T cell therapy) in its hundreds of millions of RMB Series A financing;
- TaiLai Biosciences (multi-omics oncology early screening) in its early round of financing;
- Yunfeng Capital in its Series D investment in Nanos Medical (otolaryngology diagnosis treatment platform);
- Huagai Capital in its over RMB 100 million Series A investment in NK Cell Tech (NK cell therapy);
- Huagai Capital in its over RMB 100 million Series A investment in MindRank (AI pharmaceutical);
- WeMed Medical (high-end interventional diagnosis and treatment equipment) in its RMB 100 million Series C+ financing led by Hillhouse;
- Lake Bleu in its late round of equity investment in multiple well-known medical projects;
- GSR Venture in its early round of investment in Cloudpick (AI unmanned technology);
- Northern Light Venture Capital in its early round of venture capital investment in a number of high-end manufacturing and new material companies (such as AROMEM);
- JLSemi (network communication chip design) in its over US\$100 million multiple series financing and its foreign investment;
- Am-Micro (semiconductor) in its early round of equity financing and its day-to-day operation;
- CATL (ALT) in its investment in an electric vehicle brand.

2. Mergers & Acquisitions and Reorganization

Ms. Li's experience includes providing legal services for:

- Guoda Drugstore in its RMB 2.77 billion investment by international strategic investor Walgreens Boots Alliance;
- ABclonal (antibody and molecular enzyme reagents) in its acquisition of 100% equity of Yurogen Biosystems;
- Celepixel Technology (dynamic vision sensor) in its sale of the controlling stake to OMNIVISION;
- Yum China (the parent company of KFC) in its acquisition of the controlling stake in a Chinese restaurant brand, Huangjihuang Group;
- ST Phi Therapeutics (Car-T cell therapy) in its pre-financing restructuring;
- A well-known US-funded PE in an internet advertising giant group's restructuring and the sale of it to multiple parties for hundreds of millions of RMB;
- Liangyihui in its strategic investment in ECRF (electronic clinical service platform);
- Phaeno Thera (innovative anti-infective drug) in its pre-financing restructuring.

3. Intellectual Property Licensing and Commercial Transactions

Ms. Li's experience includes providing legal services for:

- Leads Biolabs in its high-value cross-border IP licensing to BeiGene for US\$772 million;
- N1 Life Inc. (drug delivery system) in its IP licensing and the establishment of a joint venture with Accuredit;
- Dongruilang in its acquisition of IP licensing from an Israeli biopharmaceutical company and the establishment of a joint venture;
- ST Phi Therapeutics (Car-T cell therapy) in its IP licensing to Livzon Group;
- WuXi AppTec's Southeast Asia Healthcare Fund in its acquisition of IP licensing of two assets;
- Transcenta and Alebund in the establishment of an R&D joint venture, IP licensing, and commercialization transactions.